4-((4-nitrophenyl)thio)tetrahydro-2H-pyran

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((4-nitrophenyl)thio)tetrahydro-2H-pyran
• 英文别名: 4-[(4-nitrophenyl)sulfanyl]oxane
• 化学式: C₁₁H₁₃NO₃S
• 分子量: 239.295
• InChiKey: BJWBZYXDQSEWMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.87
• 重原子数：
  16.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  52.37
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  4-((4-nitrophenyl)thio)tetrahydro-2H-pyran 在 palladium 10% on activated carbon 、 氢气 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 3.0h， 生成 4-((tetrahydro-2H-pyran-4-yl)sulfonyl)aniline
  参考文献：
  名称：

  [EN] CYCLOPROPYL AMIDE DERIVATIVES
  [FR] DÉRIVÉS D'AMIDE CYCLOPROPYLE

  摘要：

  本发明涉及某些环丙基酰胺化合物，包括这些化合物的药物组合物，以及使用这些化合物和药物组合物治疗白血病和实体肿瘤、炎症性疾病、骨质疏松症、动脉粥样硬化、肠易激综合征和其他疾病和医疗状况的方法。本发明还涉及某些环丙基酰胺化合物用于抑制烟酰胺磷酸核糖转移酶（"NAMPT"）。

  公开号：

  WO2014074715A1
• 作为产物：
  描述：

  四氢吡喃-4-醇 、 4-硝基苯硫醇 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以51%的产率得到4-((4-nitrophenyl)thio)tetrahydro-2H-pyran
  参考文献：
  名称：

  [EN] CYCLOPROPYL AMIDE DERIVATIVES
  [FR] DÉRIVÉS D'AMIDE CYCLOPROPYLE

  摘要：

  本发明涉及某些环丙基酰胺化合物，包括这些化合物的药物组合物，以及使用这些化合物和药物组合物治疗白血病和实体肿瘤、炎症性疾病、骨质疏松症、动脉粥样硬化、肠易激综合征和其他疾病和医疗状况的方法。本发明还涉及某些环丙基酰胺化合物用于抑制烟酰胺磷酸核糖转移酶（"NAMPT"）。

  公开号：

  WO2014074715A1

文献信息

• Inhibitors of syk and JAK protein kinases
  申请人：Jia Zhaozhong

  公开号：US20100048567A1

  公开（公告）日：2010-02-25

  The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-V的化合物及其互变异构体或药学上可接受的盐、酯和前药，其是syk激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，包含这种化合物的制药组合物，抑制syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由syk激酶活性介导的多种疾病的方法，例如不良血栓和非何杰金淋巴瘤。
• INHIBITORS OF SYK AND JAK PROTEIN KINASES
  申请人：Jia Zhaozhong

  公开号：US20120101275A1

  公开（公告）日：2012-04-26

  The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-V和其互变异构体或药学上可接受的盐、酯和前药的化合物，其为syk激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，含有这种化合物的制药组合物，抑制syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由syk激酶活性介导的多种情况的方法，如非霍奇金淋巴瘤和不良血栓形成。
• Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response
  作者：Daniel P. Flaherty、Justin R. Miller、Danielle M. Garshott、Michael Hedrick、Palak Gosalia、Yujie Li、Monika Milewski、Eliot Sugarman、Stefan Vasile、Sumeet Salaniwal、Ying Su、Layton H. Smith、Thomas D. Y. Chung、Anthony B. Pinkerton、Jeffrey Aubé、Michael U. Callaghan、Jennifer E. Golden、Andrew M. Fribley、Randal J. Kaufman

  DOI：10.1021/ml5003234

  日期：2014.12.11

  Cellular proteins that fail to fold properly result in inactive or disfunctional proteins that can have toxic functions. The unfolded protein response (UPR) is a two-tiered cellular mechanism initiated by eukaryotic cells that have accumulated misfolded proteins within the endoplasmic reticulum (ER). An adaptive pathway facilitates the clearance of the undesired proteins; however, if overwhelmed, cells trigger apoptosis by upregulating transcription factors such as C/EBP-homologous protein (CHOP). A high throughput screen was performed directed at identifying compounds that selectively upregulate the apoptotic CHOP pathway while avoiding adaptive signaling cascades, resulting in a sulfonamidebenzamide chemotype that was optimized. These efforts produced a potent and selective CHOP inducer (AC(50) = 0.8 mu M; XBP1 > 80 mu M), which was efficacious in both mouse embryonic fibroblast cells and a human oral squamous cell cancer cell line, and demonstrated antiproliferative effects for multiple cancer cell lines in the NCI-60 panel.
• 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS
  申请人：Portola Pharmaceuticals, Inc.

  公开号：EP2323993B1

  公开（公告）日：2015-06-03
• US8063058B2
  申请人：——

  公开号：US8063058B2

  公开（公告）日：2011-11-22